Form 4: Maravai LifeSciences CFO Rajesh Asarpota Awarded Significant Equity Compensation

Maravai LifeSciences Holdings, Inc. Chief Financial Officer Rajesh Asarpota has been granted 500,000 restricted stock units, 333,333 stock options, and 750,000 performance stock units, all vesting over three years subject to continued employment and performance conditions.

Summary

• Rajesh Asarpota, Chief Financial Officer of Maravai LifeSciences Holdings, Inc. (MRVI), was granted significant equity awards on June 30, 2025.
• The awards include 500,000 Restricted Stock Units (RSUs), 333,333 Employee Stock Options, and 750,000 Performance Stock Units (PSUs).
• The RSUs and stock options vest over a three-year period, with one-third vesting on the first anniversary of the grant date and the remaining two-thirds vesting in 24 substantially equal monthly installments.
• The Employee Stock Options have an exercise price of $2.41 and are set to expire on June 30, 2035.
• The Performance Stock Units (PSUs) are performance-based, contingent on the volume-weighted average price (VWAP) of Class A Common Stock meeting or exceeding certain thresholds for 30 consecutive trading days immediately preceding the third anniversary of the grant date (July 30, 2028).
• All awarded units and options are subject to Mr. Asarpota's continued employment with the Issuer.
• All grants were made under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan.

Sentiment

Score: 7

Explanation: The document reports significant equity compensation grants to a key executive, which is generally positive for executive retention and alignment with shareholder interests. The inclusion of performance-based units further strengthens this alignment. There are no negative disclosures.

Positives

• Significant equity grants to the Chief Financial Officer align executive interests with long-term shareholder value.
• The multi-year vesting schedules for RSUs and stock options incentivize executive retention and commitment.
• Performance-based stock units (PSUs) directly link a substantial portion of compensation to the company's stock price performance, promoting value creation.

Risks

• Vesting of Restricted Stock Units (RSUs) and Employee Stock Options is contingent on the Reporting Person's continued employment with the Issuer.
• Vesting of Performance Stock Units (PSUs) is subject to the Class A Common Stock's volume-weighted average price (VWAP) meeting specific thresholds over a 30-day period preceding the third anniversary of the grant date.
• Failure to meet the specified performance thresholds for PSUs would result in the forfeiture of those units.

Future Outlook

The grants indicate a long-term commitment to the Chief Financial Officer, with vesting schedules extending over three years and option expiration in 2035, suggesting an expectation of continued operations and potential growth. The performance-based PSUs tie executive incentives to future stock price appreciation.

Industry Context

Executive equity compensation, particularly through a mix of restricted stock units, stock options, and performance-based units, is a standard practice across various industries, including life sciences. This approach aims to align executive incentives with long-term shareholder value creation and to retain key talent. The structure of these grants, featuring multi-year vesting and performance hurdles, is typical for senior executive awards in publicly traded companies.

Comparison to Industry Standards

• The utilization of a combination of time-based (RSUs, options) and performance-based (PSUs) equity awards is a common and generally accepted practice in executive compensation across publicly traded companies, including those within the life sciences sector.
• Three-year vesting periods for time-based awards are standard for executive retention and long-term incentive plans.
• Performance-based vesting tied to stock price thresholds, as observed with the PSUs, represents a strong corporate governance practice that directly links executive payouts to shareholder returns, comparable to similar plans at industry peers such as Thermo Fisher Scientific (TMO) or Danaher Corporation (DHR), which frequently incorporate stock performance metrics in their long-term incentive programs.

Corporate Governance

Related Party Transactions

• The document details equity compensation grants to Rajesh Asarpota, the Chief Financial Officer, which constitutes a transaction between the company and a key management personnel.

Stakeholder Impact

• Shareholders: Potential positive impact due to enhanced alignment of executive incentives with stock performance and the retention of key talent.
• Employees: No direct impact on general employees is mentioned, but the grants highlight the company's executive compensation strategy.

Next Steps

• Continued employment of Rajesh Asarpota with Maravai LifeSciences Holdings, Inc.
• Vesting of RSUs and stock options on a scheduled basis over three years, commencing on June 30, 2026.
• Assessment of the Class A Common Stock's volume-weighted average price (VWAP) performance leading up to July 30, 2028, for the vesting of Performance Stock Units (PSUs).

Key Dates

Recommendation

Keywords

Maravai LifeSciences, MRVI, SEC Form 4, Equity Compensation, Restricted Stock Units, RSUs, Stock Options, Performance Stock Units, PSUs, Executive Compensation, CFO, Rajesh Asarpota, Omnibus Incentive Plan, Vesting, Corporate Governance